Enanta Pharmaceuticals (ENTA) PT Raised to $78.00 at Royal Bank of Canada

Enanta Pharmaceuticals (NASDAQ:ENTA) had its price objective lifted by investment analysts at Royal Bank of Canada to $78.00 in a research note issued on Thursday. The brokerage currently has a “sector perform” rating on the biotechnology company’s stock. Royal Bank of Canada’s target price points to a potential upside of 6.24% from the company’s previous close.

Several other research firms have also recently commented on ENTA. TheStreet raised shares of Enanta Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Wednesday, December 13th. JPMorgan Chase & Co. cut shares of Enanta Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Thursday. Finally, Zacks Investment Research cut shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $51.25.

Enanta Pharmaceuticals (ENTA) traded down $1.24 during trading on Thursday, hitting $73.42. 460,761 shares of the company’s stock traded hands, compared to its average volume of 249,382. Enanta Pharmaceuticals has a 1 year low of $25.92 and a 1 year high of $95.91. The company has a market cap of $1,406.07, a PE ratio of 42.44 and a beta of 1.04.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, November 20th. The biotechnology company reported $1.86 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.13 by ($0.27). Enanta Pharmaceuticals had a return on equity of 13.33% and a net margin of 26.35%. The firm had revenue of $75.93 million for the quarter, compared to the consensus estimate of $73.80 million. During the same period in the prior year, the business earned ($0.09) EPS. Enanta Pharmaceuticals’s quarterly revenue was up 491.3% compared to the same quarter last year. research analysts anticipate that Enanta Pharmaceuticals will post 0.86 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the stock. Schwab Charles Investment Management Inc. raised its holdings in shares of Enanta Pharmaceuticals by 0.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 53,616 shares of the biotechnology company’s stock worth $1,930,000 after purchasing an additional 304 shares during the period. Vanguard Group Inc. raised its holdings in shares of Enanta Pharmaceuticals by 6.9% in the 2nd quarter. Vanguard Group Inc. now owns 847,021 shares of the biotechnology company’s stock worth $30,475,000 after purchasing an additional 54,856 shares during the period. BNP Paribas Arbitrage SA raised its holdings in shares of Enanta Pharmaceuticals by 69.1% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 7,456 shares of the biotechnology company’s stock worth $349,000 after purchasing an additional 3,047 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Enanta Pharmaceuticals by 1.4% in the 3rd quarter. Dimensional Fund Advisors LP now owns 562,394 shares of the biotechnology company’s stock worth $26,320,000 after purchasing an additional 7,617 shares during the period. Finally, Ameriprise Financial Inc. raised its holdings in shares of Enanta Pharmaceuticals by 23.5% in the 3rd quarter. Ameriprise Financial Inc. now owns 143,817 shares of the biotechnology company’s stock worth $6,730,000 after purchasing an additional 27,342 shares during the period. 67.86% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/11/enanta-pharmaceuticals-enta-pt-raised-to-78-00-at-royal-bank-of-canada.html.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply